Abstract

P-054 - Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
P1-12-2 - A Retrospective Analysis of the Efficacy and Safety of Regorafenib in Patients with Chemo-Refractory Colorectal Cancer
Takayuki Oishi ... Hidekazu Shirota
Annals of Oncology | VOL. 25
Takayuki Oishi, et. al.Takayuki Oishi ... Hidekazu Shirota
01 Oct 2014
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib
François Bertucci ... Olivier Mir
European Journal of Cancer | VOL. 126
François Bertucci, et. al.François Bertucci ... Olivier Mir
06 Jan 2020
Response to letter entitled: Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study
Jean-Yves Blay ... Sylvie Chabaud
European Journal of Cancer | VOL. 157
Jean-Yves Blay, et. al.Jean-Yves Blay ... Sylvie Chabaud
08 Sep 2021
Faculty Opinions recommendation of Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Florence Duffaud
-
Florence DuffaudFlorence Duffaud
03 Aug 2012
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Re: Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
Elio Mazzone ... Francesco Montorsi
Annals of Oncology | VOL. -
Elio Mazzone, et. al.Elio Mazzone ... Francesco Montorsi
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
View more papers